Christie Ballantyne, MD, explains how the CORALreef Extension study adds safety exposure and shows LDL-C lowering with oral enlicitide is sustained over time.
Commentary|Articles|June 24, 2026
ADA 2026: Diabetes Technology Innovations Expand Beyond Traditional CGM Use
Fact checked by: Gillian McGovern, Editor, Ron Panarotti
As these tools continue to move into mainstream diabetes management, it is increasingly important that pharmacists have proficiency.
Advertisement
Advertisement
The technology presentations at the 86th American Diabetes Association (ADA) Scientific Sessions highlighted a major shift in diabetes care. Continuous glucose monitoring (CGM) is moving beyond intensive insulin management and becoming a broader therapeutic tool for people with type 2 diabetes (T2D), while automated insulin delivery systems continue to expand and emerging ketone monitoring technologies promise to improve safety and reduce the risk of diabetic ketoacidosis (DKA).
Related to this article
The glucagon/GLP-1 dual agonist did not raise major adverse cardiovascular event risk in adults with obesity, but GI-related discontinuations were high.
Post hoc AHA 2026 data show the oral GLP-1 receptor agonist lowered systolic blood pressure across hypertension stages, partly beyond weight loss.
Early metformin may curb insulin starts in gestational diabetes, while a separate analysis ties a history of the condition to advanced CKM syndrome.
Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.
RSV hospitalization raised short-term invasive pneumococcal disease risk, especially among unvaccinated individuals.
ADA guidance ties monitoring choices to therapy, risk, and preference. Brooke Hudspeth, PharmD, explains how pharmacists help individualize the plan.
Two Kidney Week 2026 posters suggest remnant cholesterol–based markers may help stratify CKD severity and cardiovascular death risk on hemodialysis.
Advertisement
Advertisement